Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braveheart Bio, Inc.BRVE · Entity 4564 | Chief Financial Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braveheart Bio, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 520,927 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 27,777 · Balance 520,927 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-08-04 | Direct | 300,000 |
Reported balance
After 2026-08-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-05 · Grant · Acquired 300,000 · Balance 300,000 F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Rickey Trust CR | 91,324 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 91,324 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Rickey Trust BR | 91,324 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 91,324 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 20, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,200 |
Reported balance
After 2024-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-20 · Disposition to issuer · Disposed 26,761 · Balance 31,200 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-05-20 · Disposition to issuer · Disposed 31,200 · Balance 0 F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 836 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2027-04-11 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 137 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 143 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2030-01-22 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 1,214 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 112,945 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9: One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 112,500 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F10: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-05-20 · Disposition to issuer · Disposed 108,999 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.33 · Expires 2034-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-05-20 · Disposition to issuer · Disposed 78,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.
F4: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.
F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F9: One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
F10: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F11: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
F12: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 20:41 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | PurchaseCommon Stock | 27,777 | $18.00 | $499,986.00 |
DisclosureSEC source: 0001470831-26-000804 · wk-form4_1786135298.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,927 Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:41 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000804 · wk-form4_1786135298.xml · derivative · entry 4 Rickey James Paul · CIK 0001606243 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-08-04 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 78,000 | Not disclosed Strike: $18.33 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 10 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,000 shares Expires 2034-01-03 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 108,999 | Not disclosed Strike: $7.55 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 9 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,999 shares Expires 2033-01-03 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 112,500 | Not disclosed Strike: $13.30 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 8 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,500 shares Expires 2032-01-03 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F10 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 112,945 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 7 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,945 shares Expires 2031-01-04 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 1,214 | Not disclosed Strike: $3.23 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 6 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,214 shares Expires 2030-01-22 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 143 | Not disclosed Strike: $6.51 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 5 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 143 shares Expires 2029-02-05 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 137 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 4 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 137 shares Expires 2027-04-11 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 836 | Not disclosed Strike: $11.31 | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · derivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 836 shares Expires 2028-01-01 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 31,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 26,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000094 · wk-form4_1716250016.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,200 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3 · balance_after: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 398 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 12 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137 Underlying: Common Stock · 398 shares Expires 2027-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F8 · derivative.exercise_date: 100% of shares underlying the option were fully vested as of April 1, 2021. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 18,286 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 11 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,214 Underlying: Common Stock · 18,286 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 23, 2024. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 164 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 10 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836 Underlying: Common Stock · 164 shares Expires 2028-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 2, 2022. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 857 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 9 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143 Underlying: Common Stock · 857 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of February 6, 2023. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 7,055 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 8 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,945 Underlying: Common Stock · 7,055 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 1 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · derivative · entry 7 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,999 Underlying: Common Stock · 1 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 398 | $5.02 | $1,997.96 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 6 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 18,286 | $3.23 | $59,063.78 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 5 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 164 | $11.31 | $1,854.84 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 4 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 857 | $6.51 | $5,579.07 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 7,055 | $13.20 | $93,126.00 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 10, 2024 01:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 1 | $7.55 | $7.55 |
DisclosureSEC source: 0001626199-24-000066 · wk-form4_1715303576.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 44,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · derivative · entry 9 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 44,000 shares Expires 2028-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 2, 2022. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 73,764 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · derivative · entry 8 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 73,764 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F4 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of February 6, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 44,000 | $25.00 | $1,100,000.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 6 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 44,000 | $11.31 | $497,640.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 5 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 73,764 | $22.31 | $1,645,829.74 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 4 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 73,764 | $6.51 | $480,203.64 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| January 25, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 236 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · derivative · entry 7 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,764 Underlying: Common Stock · 236 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F4 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of February 6, 2023. Read SEC document |
| January 25, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 236 | $22.00 | $5,192.00 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| January 25, 2024 Filed Jan 30, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 236 | $6.51 | $1,536.36 |
DisclosureSEC source: 0001626199-24-000027 · wk-form4_1706573047.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 78,000 | $0.00 Strike: $18.33 | $0.00 |
DisclosureSEC source: 0001626199-24-000023 · wk-form4_1704496038.xml · derivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2034-01-03 F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 31,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001626199-24-000023 · wk-form4_1704496038.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,200 F1 · price: Received grant of restricted stock units ("RSUs") for no consideration. One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025 July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:35 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 15,213 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001626199-23-000145 · wk-form4_1703205343.xml · derivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535 Underlying: Common Stock · 15,213 shares Expires 2027-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F3 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of April 1, 2021. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:35 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 15,213 | $19.21 | $292,221.95 |
DisclosureSEC source: 0001626199-23-000145 · wk-form4_1703205343.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.01 to $19.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:35 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 15,213 | $5.02 | $76,369.26 |
DisclosureSEC source: 0001626199-23-000145 · wk-form4_1703205343.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 1,800 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · derivative · entry 9 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,748 Underlying: Common Stock · 1,800 shares Expires 2027-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of April 1, 2021. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 1,800 | $19.00 | $34,203.06 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 6 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 1,800 | $5.02 | $9,036.00 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 5 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 45,387 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · derivative · entry 8 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,548 Underlying: Common Stock · 45,387 shares Expires 2027-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of April 1, 2021. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 45,387 | $19.09 | $866,383.37 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 4 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 45,387 | $5.02 | $227,842.74 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 11,600 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · derivative · entry 7 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,935 Underlying: Common Stock · 11,600 shares Expires 2027-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of April 1, 2021. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 11,600 | $19.00 | $220,405.80 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 02:20 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 11,600 | $5.02 | $58,232.00 |
DisclosureSEC source: 0001606243-23-000006 · wk-form4_1702952400.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 00:31 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 6,446 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · derivative · entry 9 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 6,446 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 00:31 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 6,446 | $16.08 | $103,649.75 |
DisclosureSEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 6 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.15. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 00:31 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 6,446 | $3.23 | $20,820.58 |
DisclosureSEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 5 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.